Rapid Communication
Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Feb 7, 2008; 14(5): 741-746
Published online Feb 7, 2008. doi: 10.3748/wjg.14.741
Table 2 Morphological, histological, microbiological, serological and treatment-related features n (%)
CharacteristicsCDGITBP value
(n = 26)(n = 26)
Sites of involvement
Oesophagus0 (0)1 (3.8)NS
Stomach0 (0)2 (7.7)NS
Duodenum1 (3.8)2 (7.7)NS
Jejunum2 (7.7)1 (3.8)NS
Ileum16 (61.5)20 (76.9)NS
Ileo-cecal valve20 (76.9)21 (80.7)NS
Right colon18 (69.2)21 (80.7)NS
Left colon10 (38.4)5 (19.2)NS
Rectum8 (30.7)5 (19.2)NS
Anal and perianal region2 (7.7)1 (3.8)NS
Endoscopic and/or surgical findings
Skip lesions6 (23.1)2 (7.7)NS
Deep linear/serpiginous ulcers15 (57.7)6 (23.1)S
Aphthous ulcers9 (34.6)5 (19.2)NS
Stricture8 (30.7)5 (19.2)NS
Cobble-stone appearance15 (57.7)6 (23.1)S
Pseudo polyps9 (34.6)5 (19.2)NS
Neoplasm-like appearance0 (0)2 (7.7)NS
Fistula3 (11.5)0 (0)NS
Histological features
Granuloma8 (30.7)15 (57.7)NS
Caseation0 (0)9 (34.6)S
Confluence0 (0)6 (23.1)S
Interpreted as IBD by pathologist10 (38.4)3 (11.5)S
Interpreted as TB by pathologist0 (0)13 (50)S
Interpreted as non-specific chronic inflammation by pathologist16 (61.6)10 (38.4)NS
AFB smear/culture positivity0 (0)6 (23.1)S
TB PCR positivity0 (0)17 (65.4)S
Serological features
p-ANCA1 (3.8)1 (3.8)NS
c-ANCA1 (3.8)0 (0)NS
IgA ASCA10 (38.4)6 (23.1)NS
IgG ASCA10 (38.4)11 (42.3)NS
Treatment-related factors
Recurrence after surgery, n/total patients underwent surgery (%)7/9 (77.7)0/4 (0)S
Number of patients previously treated with ATT (without any response)9 (34.6)--
Complete response to ATT-26 (100)-